
Oyebimpe Oluyemisi Adesina MD
Sickle Cell & Other Anemias
Assistant Professor, University of Washington, Seattle, WA
Join to view full profile
825 Eastlake Ave EMS# CE3-300Seattle, WA 98109
Phone+1 206-606-1621
Dr. Adesina is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2012 - 2015
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2009 - 2011
University of California San Francisco School of MedicineClass of 2008
Certifications & Licensure
CA State Medical License 2009 - 2027
WA State Medical License 2016 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Publications & Presentations
PubMed
- Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis.Shaina M Willen, Ann M Brunson, Oyebimpe O Adesina, Ted Wun
American Journal of Hematology. 2026-10-01 - Prevalence of Low Bone Mineral Density Increases With Age in Sickle Cell Disease.Jahnavi Gollamudi, Chengzhou Wu, Guolian Kang, Michael Sexton Lamonica, Pei-Lin Chen
Ejhaem. 2026-06-01 - 2 citationsLow bone mineral density and pain impact in adults with sickle cell disease.Oyebimpe O Adesina, Jenna Voutsinas, Qian V Wu, Leyla Y Teos, Mehrad Rokni
Blood Advances. 2026-02-10
Press Mentions
Sickle Cell in the ED: Part 3February 19th, 2024
Sickle Cell in the ED: Part 1January 17th, 2024
A Game-Changing Cure for Sickle Cell May Be ComingNovember 2nd, 2023
Grant Support
- A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell diseaseUNIVERSITY OF CALIFORNIA AT DAVIS2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: